Angiographic Geometric Changes of the Lumen Arterial Wall After Bioresorbable Vascular Scaffolds and Metallic Platform Stents at 1-Year Follow-Up  by Gomez-Lara, Josep et al.
RR
R
C
M
i
w
b
R
t
d
w
(
t
m
(
C
d
a
S
(
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 4 , N O . 7 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 1 . 0 4 . 0 0 9Angiographic Geometric Changes of the Lumen
Arterial Wall After Bioresorbable Vascular Scaffolds
and Metallic Platform Stents at 1-Year Follow-Up
Josep Gomez-Lara, MD,* Salvatore Brugaletta, MD,* Vasim Farooq, MBCHB,*
obert Jan van Geuns, MD, PHD,* Bernard De Bruyne, MD, PHD,† Stephan Windecker, MD,‡
Dougal McClean, MD,§ Leif Thuesen, MD, Dariusz Dudek, MD,¶ Jacques Koolen, MD, PHD,#
Robert Whitbourn, MD,** Pieter C. Smits, MD, PHD,†† Bernard Chevalier, MD,‡‡
Marie-Angèle Morel, BSC,§§ Cécile Dorange, MSC, Susan Veldhof, RN,
ichard Rapoza, PHD,¶¶ Hector M. Garcia-Garcia, MD, PHD,*§§
John A. Ormiston, MBCHB, PHD,## Patrick W. Serruys, MD, PHD*
otterdam and Eindhoven, the Netherlands; Aalst and Diegem, Belgium; Bern, Switzerland;
hristchurch and Auckland, New Zealand; Skejby, Denmark; Krakow, Poland;
elbourne, Australia; Massy, France; and Santa Clara, California
Objectives The aim of this study was to compare the angiographic changes in coronary geometry of the
bioresorbable vascular scaffolds (BVS) and metallic platform stent (MPS) between baseline and follow-up.
Background Coronary geometry changes after stenting might result in wall shear stress changes and ad-
verse events. The BVS have better conformability, compared with MPS, but still modify artery geometry. It is
uncertain whether the BVS resorption can restore the coronary anatomical conﬁguration at midterm follow-up.
Methods All patients of the ABSORB (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary
Stent System [BVS EECSS] in the Treatment of Patients With de Novo Native Coronary Artery Lesions) and
SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of
Patients With de Novo Native Coronary Artery Lesions) trials treated with a single 3.0  18 mm device and
maged at baseline and 6- to 12-month follow-up were eligible. Coronary geometry changes were assessed
ith quantitative angiography as changes in curvature and angulation. Curvature and angulation changes
etween systole and diastole were investigated to assess hinging movements of the coronary artery.
esults One hundred sixty-one patients (86 BVS, and 75 MPS) were included. Baseline angiographic charac-
eristics were similar. From post-implantation to follow-up, curvature increased 8.4% (p  0.01) with BVS and
ecreased 1.9% (p  0.54) with MPS; p  0.01. Angulation increased 11.3% with BVS (p  0.01) and 3.8%
ith MPS (p  0.01); p  0.01. From pre-implantation to follow-up, BVS decreased 3.4% the artery curvature
p  0.05) and 3.9% the artery angulation (p  0.16), whereas MPS presented with 26.1% decrease in curva-
ure (p  0.01) and 26.9% decrease in angulation (p  0.01), being larger with MPS (p  0.01, both). Hinging
ovements in curvature from pre-implantation to follow-up decreased 19.7% with BVS and 39.0% with MPS
p  0.27) and decreased 3.9% with BVS and 26.9% with MPS in angulation (p  0.01).
onclusions At midterm follow-up, the BVS tended to restore the coronary conﬁguration and the systo-
iastolic movements to those seen before implantation. The coronary geometry remained similar to that seen
t after implantation with MPS. (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent
ystem [BVS EECSS] in the Treatment of Patients With de Novo Native Coronary Artery Lesions; NCT00856856)
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790Coronary geometry is the major determinant of the shear stress
inflicted on the endothelial cells lining the artery wall. Physi-
ological wall shear stress (WSS) induces the alignment of the
endothelial cells in the flow direction and the secretion of
numerous antiatherogenic substances such as endothelin and
nitric oxide. In contrast, oscillatory or low WSS induces the
secretion of pro-atherogenic substances, which carries a higher
risk of plaque progression (1). As a result, atherosclerotic
plaques are more frequently located at regions with low WSS,
such as at the inner walls of curved arteries (2–4).
See page 800
Coronary stenting also modifies shear stress. The local WSS
decreases along the entire length of the stent after implantation
(5). Moreover, stented regions ex-
posed to lower WSS have been
shown to exhibit higher grades of
neointimal response compared
with regions with physiological
WSS; this has been shown to be
applicable for both bare-metal
stents (BMS) and paclitaxel-
eluting stents (PES) at 6-month
follow-up (6,7). Consequently,
straightening of curved coronary
arteries after implantation has
been related to a higher neointi-
mal response with BMS and PES
at midterm follow-up (7–9). Con-
versely, sirolimus-eluting stents
(SES) have been demonstrated to
avoid the relationship between
low WSS and a higher neointimal
response at 6 months (7). As a
result, some clinical studies using
first-generation SES showed no
relationship between angulated le-
sions and angiographic restenosis
t 9 months (10,11). It is still unknown whether the progres-
ive loss of angiographic minimal lumen diameter (MLD)
xperienced by the SES at long-term follow-up can modify the
elationships among artery bend, curvature, and angulation
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M
aith stent restenosis (12). At 2 years, SES and PES presented
ith similar angiographic lumen loss (12).
The most important device property that determines
cute changes in coronary geometry is the conformability of
he stent. Stent conformability is dependent on both mate-
ial and design (13). The everolimus-eluting bioresorbable
ascular scaffold (BVS) have shown better conformability in
ts ability to adapt to the coronary geometry immediately
fter implantation, compared with the Multi-link Vision
nd Xience V metallic platform stents (MPS) (Abbott
ascular, Santa Clara, California) (14). However, both the
PS and BVS devices have previously been demonstrated
o decrease the artery curvature and angulation from pre- to
ost-implantation (14). Therefore, it is uncertain how these
hanges in artery geometry are maintained in both devices at
idterm follow-up. This fact is especially important with
he BVS, because bioresorption of the polymeric scaffolds
ight potentially allow for the restoration of the coronary
rtery to its original anatomical configuration seen before
mplantation. By design, the mechanical integrity of the
VS and the scaffold support to the artery wall eventually
isappear a few months after the implantation (15), with
omplete resorption of the polymer approximately 2 years
fter implantation (16).
The aim of the present study is to compare the changes in
oronary geometry from post-implantation to 6 to 12
onths of follow-up between BVS and MPS. The clinical
utcomes of both BVS and MPS are also explored.
ethods
Population and study design. The ABSORB Cohort B (A
Clinical Evaluation of the Bioabsorbable Everolimus Elut-
ing Coronary Stent System [BVS EECSS] in the Treat-
ment of Patients With de Novo Native Coronary Artery
Lesions) trial is a single-arm trial that included 101 patients
treated with a single 3.0  18 mm BVS. The global
opulation was divided into 2 groups with different invasive
ngiographic controls at 6-month (n  45) and 12-month
n  56) follow-up. The study design and the clinical
utcomes of the first cohort of patients (with 6-month
ollow-up invasive control) have been reported (17). The
PIRIT (A Clinical Evaluation of the XIENCE V Everoli-
ordis, Cook, Eli Lilly, EuroCor, GlaxoSmithKline, Invatec, Medtronic, The
edicines Company, Merck Sharp & Dohme, Nycomed, Orbus-Neich, Pfizer,
ossis, Promed, Sanofi-Aventis, Siemens, Solvay, Terumo, and Tyco. Dr. Smits
as received speaker and travel fees from Abbott Vascular. Dr. Chevalier is a
onsultant for Abbott Vascular. Cécile Dorange, Susan Veldhof, and Dr. Rapoza
re employees of Abbott Vascular. Dr. Ormiston is on the advisory boards for
bbott and Boston Scientific; and has received minor honoraria from Abbott and
oston Scientific. All other authors have reported that they have no relationships
o disclose. Eric Bates, MD, served as Guest Editor for this paper.anuscript received January 25, 2011; revised manuscript received March 29, 2011,
ccepted April 11, 2011.
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791mus Eluting Coronary Stent System in the Treatment of
Patients With de Novo Native Coronary Artery Lesions) I
trial is a randomized trial that included 60 patients treated
with a single Xience V (n 28) or a Multi-link Vision (n
32) 3.0  18 mm stent. The SPIRIT II trial randomized 300
patients to PES or to Xience V stent. A total of 223 patients were
treated with different sizes of Xience V stent. All patients included
in the SPIRIT I and II trials were scheduled for an angiographic
control at 6-month follow-up.
The study design and clinical outcomes of the SPIRIT I
and II trials have been reported (18,19). In brief, the
inclusion criteria of the ABSORB and SPIRIT trials were
similar: patients with stable or non–ST-segment elevation
acute coronary syndrome and with a de novo lesion in a
native coronary artery with a diameter stenosis (DS) be-
tween 50% and 99% were eligible. Patients with ostial
lesions, heavily calcified arteries, or extreme angulated
lesions (90°) were excluded.
Acute changes in coronary geometry assessed before and
after implantation of both BVS and MPS (Multi-link
Vision or Xience V) have previously been investigated and
reported by our group (14). In brief, 89 patients included in
the ABSORB Cohort B trial treated with the BVS and 102
patients of the SPIRIT I and II trials treated with the
Multi-link Vision or Xience V stents were included (14).
This report presents a continuation of the previous study
with the same population that underwent angiographic
control at 6- or 12-month follow-up.
Treatment procedure and devices. All lesions were treated
with routine interventional techniques that included manda-
tory pre-dilation with a balloon shorter and 0.5 mm smaller in
diameter than the study device. Post-dilation with a balloon
shorter than the implanted device was allowed at the discretion
of the operator, as was bailout treatment.
The ABSORB Bioabsorbable Vascular Scaffold (Abbott
Vascular) is a device consisting of a backbone of a fully
resorbable polymer (poly-L-lactide), coated with a copoly-
mer (poly-D,L-lactide) that contains and releases the anti-
proliferative drug (everolimus). Two platinum markers at
each end outline the boundaries of the scaffold and remain
embedded in the coronary wall after the scaffold resorbs.
The Multi-link Vision and the Xience V stents (Abbott
Vascular) share the same metallic platform composed of a
cobalt-chromium alloy. The Xience V stent is coated with a
biocompatible fluorinated copolymer that contains and re-
leases the same amount of antiproliferative drug (100
g/cm2 of everolimus) within a similar period.
Quantitative coronary angiography analysis. The operators
ere requested to select an angiographic view with minimal
oreshortening of the lesion and limited overlap with other
rteries. This angiographic view was used at baseline (before
nd after implantation) and at follow-up. The 2-dimensional
ngiograms were analyzed by an independent core labora-
ory (Cardialysis, Rotterdam, the Netherlands) with theAAS II analysis system (Pie Medical BV, Maastricht, the
etherlands). In each patient, the treated region and the peri-
reated regions (defined by 5 mm proximal and distal to the
evice edge) were analyzed. The following quantitative
oronary angiography (QCA) parameters were measured:
he interpolated-reference artery diameter, the MLD, and
he percentage DS. Late luminal loss was derived from the
ifference between the MLD after implantation and at
ollow-up with matched angiographic views.
Curvature and angulation were measured before and after
mplantation and at follow-up with the same angiographic
iews (with a maximal difference of 10°). Both parameters
ere assessed within the treated region with clear landmarks
o assess the treated region before implantation and with the
adio-opaque markers after implantation and at follow-up.
oth curvature and angulation were estimated with QCA
CAAS II version 1.2 Beta or CAAS 5.9 research version;
ie Medical Imaging) as previously reported (14). Briefly,
curvature” is defined as the infinitesimal rate of change in
he tangent vector at each point of the center-line. This
easurement has a reciprocal relationship to the radius of
he perfect circle defined by the curve at each point. The
urvature value is calculated as 1/radius of the circle in cm1
(14). “Angulation” is defined as the angle in degrees that the
tip of an intracoronary guidewire would need to reach the
distal part of a coronary bend (14). Cyclical changes in
coronary curvature and angulation were estimated as: cur-
vature/angle at the end-diastole  curvature/angle at the
end-systole. End-diastole curvature/angulation was assessed
in the still angiographic view corresponding to the peak
of the QRS complex of the electrocardiogram; and
end-systole curvature/angulation was assessed in the still
angiographic view corresponding with the peak of the T
wave of the electrocardiogram. Relative differences, be-
fore and after implantation, were estimated at the end-
diastole as: (absolute difference in curvature or angulation
between pre- and post-implantation/curvature or angu-
lation at pre-implantation)  100.
Statistical analysis. The Kolmogorov-Smirnov test was used
to evaluate the normality assumptions of all continuous
variables. Because curvature, angulation, and cyclical
changes of curvature and angulation did not have a normal
distribution, all QCA geometry variables were expressed as
median (interquartile range). The rest of the continuous
variables were expressed as mean  1 SD. Categorical
variables were presented as counts (%). Paired comparisons
of continuous variables within groups between different
time-points were estimated with the Wilcoxon test. Non-
paired comparisons between BVS and MPS were estimated
with the Mann-Whitney U test when variables were non-
normally distributed and with the Student t test when
normally distributed. Comparisons of categorical variables
were estimated with the chi-square test.
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792To assess the interobserver reproducibility of curvature
and angle measurements, 2 observers analyzed 40 randomly
selected cases. The interobserver reproducibility was as-
sessed with the r2 Pearson correlation coefficient and the
interclass correlation coefficient for absolute agreement
(ICCa). An ICCa 0.4 indicated bad agreement, an ICCa
between 0.4 and 0.75 indicated moderate agreement, and
ICCa values 0.75 indicated excellent agreement (20).
All statistical tests were carried out with a 2-sided 5%
level of significance. All measures were obtained with the
SPSS software (version 15.0, SPSS, Inc., Chicago Illinois).
Results
Population and baseline clinical characteristics. A total of 86
atients treated with BVS and 75 patients treated with
PS (58 Xience V, and 17 Multi-link Vision) were
ncluded in the present study. A flow chart of the patient
election is shown in Figure 1. Briefly, 30 patients were
xcluded because of: declined invasive angiographic follow-
p, different angiographic views between baseline and
ollow-up, target lesion revascularization (TLR) before the
cheduled invasive control, and damage to the data storage
edia. Angiographic follow-up of the BVS group was
erformed at 6 months in 37 patients and at 12 months in
Figure 1. Flow Chart of the Patient SelectionBVS  bioresorbable vascular scaffolds; MPS  metallic platform stents.9 patients. All patients treated with MPS were planned for
nvasive angiographic follow-up at 6 months.
The baseline clinical characteristics are shown in Table 1.
oth groups were similar in age, sex, and cardiovascular risk
actors except for smoking history (BVS 16.3% vs. MPS
7.3%; p 0.01). Although there were no differences in the
treated artery, the BVS group had a trend toward more
patients with the culprit lesion located in the right coronary
artery (33.7% vs. 20.9%, respectively). The left anterior
descending was the most commonly treated artery with both
BVS and MPS (45.4% vs. 50.7%, respectively).
Angiographic changes unrelated to coronary geometry. An-
giographic findings unrelated to coronary geometry are
shown in Table 2. Both BVS and MPS showed similar
angiographic parameters before implantation. After implan-
tation the BVS demonstrated a smaller MLD (2.05 mm vs.
2.14 mm, respectively; p  0.01) and higher DS (15.4% vs.
2.7%, respectively; p  0.01) compared with MPS. At
ollow-up, the DS, MLD, and late luminal loss were
onstatistically different between BVS and MPS.
Angiographic changes related to coronary geometry. An-
giographic findings related to coronary geometry are shown
in Table 3. Before implantation both groups presented with
similar median values of curvature (BVS 0.297 cm1 and
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793MPS 0.365 cm1; p 0.99) and angulation (33.1° vs. 36.5°,
espectively; p 0.84). Cyclical changes in curvature (0.109
m1 vs. 0.091 cm1, respectively; p 0.80) and angulation
(5.6° vs. 8.4°, respectively; p  0.11) were also similar
between groups.
From pre- to post-implantation, curvature and angula-
tion significantly decreased in both groups. However, the
BVS group experienced a smaller reduction in curvature
Table 1. Baseline Clinical Characteristics
BVS (n  86) MPS (n  75) p Value
Age (yrs) 61.6 8.4 62.6 10.2 0.50
Men 62 (72.1) 52 (69.3) 0.70
Hypertension 55 (64.0) 44 (58.7) 0.47
Hypercholesterolemia 71 (82.6) 55 (73.3) 0.16
Diabetes mellitus 15 (17.4) 12 (16.0) 0.81
Smoking history 14 (16.3) 28 (37.3) 0.01
Previous MI 20 (23.3) 25 (33.3) 0.23
Previous PCI 15 (17.4) 14 (18.7) 0.84
Previous CABG 2 (2.3) 1 (1.3) 0.64
Clinical presentation 0.41
Stable angina 72 (83.7) 59 (78.7)
Acute coronary syndrome 14 (16.3) 16 (21.3)
Culprit artery 0.13
LAD 39 (45.4) 38 (50.7)
LCX 18 (20.9) 22 (29.3)
RCA 29 (33.7) 15 (20.0)
Values are mean SD or count (%).
BVS  bioresorbable vascular scaffolds; CABG  coronary artery binding graft; LAD  left
anterior descending artery; LCX  left circumflex artery; MI  myocardial infarction; MPS 
metallic platform stents; PCI percutaneous coronary intervention; RCA right coronary artery.
Table 2. Quantitative Coronary Angiography Findings
Pre-Implantation Pos
Lesion/scaffold length (mm) BVS 10.08 (3.77)
MPS 11.03 (3.69)
RVD (mm) BVS 2.60 (0.37)
MPS 2.65 (0.31)
MLD (mm) BVS 1.06 (0.27)
MPS 1.03 (0.34)
BMS 1.05 (0.31)
DES 1.03 (0.35)
LLL BVS —
MPS —
BMS
DES
DS (%) BVS 59.12 (9.90)
MPS 61.19 (11.48)
BMS 60.73 (9.34)
DES 61.32 (12.11)
Bare-metal stents (BMS) 17; drug-eluting stents (DES) 58. *p co
†p comparison between BVS and MPS after implantation; ‡p comDS diameter stenosis; LLL late luminal loss; MLDminimal lumen diame(15.3% vs. 21.9%, respectively; p  0.11) and angulation
17.4% vs. 31.8%, respectively; p  0.02) compared with
PS. The BVS also presented with a smaller decrease in
ysto-diastolic (cyclical) changes in curvature (23.1% vs.
9.9%, respectively; p  0.09) and angulation (29.6% vs.
1.0%, respectively; p  0.06) compared with MPS.
From post-implantation to follow-up, the BVS showed
n 8.4% increase in curvature (p 0.01) and 11.3% increase
n angulation (p  0.01). Conversely, the MPS remained
ith a similar curvature (1.9% reduction, p  0.54) but
resented with a mild increase in angulation (3.8%, p 
.01). The comparison of the absolute changes in curvature
nd angulation from post-implantation to follow-up be-
ween BVS and MPS was statistically significant for both
arameters. The cyclical changes in coronary curvature and
ngulation observed at follow-up were similar to that
bserved after implantation in both groups, without any
ignificant differences between devices.
From pre-implantation to follow-up, the BVS demon-
trated a trend toward a reduction in artery curvature (3.4%;
 0.05) and angulation (3.9%; p  0.16). However, the
PS demonstrated a significant reduction in curvature of
6.1% (p  0.01) and a reduction in angulation of 26.9%
p 0.01); this was shown to be significantly larger than the
VS (p  0.01 for curvature and angulation). Similarly, the
VS experienced fewer changes of systo-diastolic changes
n curvature (19.7% reduction; p  0.11) and angulation
0.3% increase; p  0.51). However, the MPS showed an
mportant decrease in cyclical changes of curvature (39.0%;
 0.01) and angulation (49.9%; p  0.01). The compar-
son between devices resulted in a lower reduction with the
seline and Follow-Up
antation Follow-Up p Value* p Value† p Value‡
(1.50) 16.33 (1.73) 0.11 0.23 0.10
(1.13) 16.87 (1.19)
(0.31) 2.53 (0.34) 0.37 0.32 0.01
(0.32) 2.68 (0.32)
(0.25) 2.05 (0.30) 0.62 0.01 0.14
(0.25) 2.14 (0.49)
(0.33) 1.51 (0.44)
(0.23) 2.33 (0.31)
0.23 (0.27) — — 0.47
0.27 (0.43)
0.89 (0.40)
0.08 (0.21)
(6.00) 20.12 (8.95) 0.76 0.01
(4.39) 20.67 (13.94)
(5.10) 39.53 (15.19)
(4.16) 14.95 (6.64)
n between BVS (n 86) andMPS (n 75) before implantation;
n between BVS and MPS at follow-up.at Ba
t-Impl
16.33
16.69
2.67
2.72
2.28
2.41
2.40
2.41
—
—
15.44
12.66
13.70
12.35
mpariso
parisoter; RVD reference vessel diameter; other abbreviations as in Table 1.
ci
s
5
c
a
a
a
s
2
t
w
c
t
0
d
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 7 , 2 0 1 1
J U L Y 2 0 1 1 : 7 8 9 – 9 9
Gomez-Lara et al.
Coronary Geometry Restoration After BVS Implantation
794BVS compared with the MPS for cyclical changes in
angulation (p  0.01) but not for the cyclical changes in
urvature (p  0.27).
Geometric changes in coronary geometry in the subset of
patients with larger pre-implantation curvature and angle.
Because geometric changes are expected to be greater in
curved arteries compared with straight arteries; the one-half
of the overall population with larger median values of
curvature (0.324 cm1) and angulation (34.3°) before
mplantation were selected and are shown in Figure 2.
From pre- to post-implantation, the BVS demonstrated a
maller reduction in curvature (from 0.579 to 0.480 cm1;
15.9%) compared with MPS (from 0.553 to 0.400 cm1;
25.5%); this difference almost reached statistical significance
when both scaffolds were compared (p  0.09). The BVS
also showed a trend toward a lower reduction in angulation
(from 57.7° to 43.9°; 20.6%) compared with MPS (from 56.7°
to 36.4°; 36.1%); without statistical significance (p  0.14).
From post-implantation to follow-up, the BVS showed a
6.2% increase in artery curvature (from 0.480 to 0.547
cm1) and a 7.8% increase in angulation (from 43.9° to
2.8°; 7.8%). The MPS demonstrated a 3.7% reduction in
urvature (from 0.400 to 0.356 cm1) and 3.2% increase in
ngulation (from 36.4° to 35.7°). As a result, the BVS had
statistically significant larger increase in curvature and
ngulation than MPS (p  0.01 for both measurements).
From pre-implantation to follow-up, the BVS demon-
trated a 0.019 cm1 (3.4%) reduction in curvature and a
6.1° (10.4%) reduction in angulation. The MPS demon-
strated a 0.211 cm1 (39.1%) reduction in curvature and a
0.1° (32.6%) reduction in angulation. The absolute reduc-
ion in curvature and angulation were significantly lower
ith the BVS compared with the MPS (p  0.01 for both
Table 3. Coronary Geometric Changes at Baseline and Follow-Up
Pre-Implantation Post-Implantation Follow-Up
Curvature (cm1) BVS 0.297 (0.179–0.573) 0.269 (0.133–0.473) 0.299 (0.154–0.
MPS 0.365 (0.186–0.556) 0.265 (0.130–0.400) 0.261 (0.133–0.
Cyclic changes in
curvature (cm1)
BVS 0.109 (0.043–0.167) 0.070 (0.032–0.149) 0.078 (0.026–0.
MPS 0.091 (0.045–0.173) 0.046 (0.022–0.100) 0.060 (0.026–0.
Angle (°) BVS 33.13 (15.62–55.40) 26.26 (13.33–43.82) 32.44 (18.86–49
MPS 36.49 (23.08–58.19) 24.94 (13.46–36.60) 24.55 (14.86–36
Cyclic changes in
angle (°)
BVS 5.64 (2.37–12.14) 4.63 (1.85–8.22) 4.51 (2.59–10.
MPS 8.35 (3.40–13.20) 3.70 (1.55–6.46) 4.54 (2.03–6.8
Values are median (interquartile range). *p comparison between BVS (n 86) and MPS (n 75) o
of the absolute difference follow-up (FU) post-implantation; ‡p comparison between BVS and
p1 paired comparison between pre- and post-implantation; p2 paired comparison between
abbreviations as in Table 1.urvature and angulation).Geometric changes of the BVS group at 6- and 12-month
follow-up. Figure 3 shows the individual data of the BVS
patients divided according to the invasive follow-up (6 vs.
12 months). From post-implantation to follow-up, the
cohort of patients who underwent 12-month follow-up
tended to have larger changes in curvature (14.8% vs. 2.9%,
respectively; p  0.24) and angulation (11.4% vs. 6.2%,
respectively; p 0.36) compared with the cohort of patients
who had 6-month follow-up.
Clinical outcomes related to coronary curvature/angulation.
A total of 191 patients (89 BVS and 102 MPS: 77 Xience
V and 25 Multi-link Vision) were investigated before
implantation for geometric parameters. There were no
deaths during the first year of follow-up. A total of 14
patients (7.3%) presented with TLR during the first 12
months after implantation: 4 patients (4.5%) treated with
the BVS, 3 patients (3.9%) treated with the Xience V stent,
and 7 patients (28.0%) treated with the Multi-link Vision
stent. None of the patients with TLR were diabetic. All
TLR events were ischemia-driven, except for 2 patients (1
BVS and 1 Multi-link Vision).
Figure 4 shows the box-plot values of curvature and angulation
before implantation according to the treatment device. In the
overall population, patients with TLR at 1 year showed larger
median values of curvature (0.454 cm1 vs. 0.307 cm1, respec-
ively; p 0.72) and angulation (41.9° vs. 31.4°, respectively; p
.23) compared with patients without TLR, although these
ifferences did not reach statistical significance.
Reproducibility of curvature and angle measurements. In-
terobserver reproducibility for curvature assessment had an r2
Pearson correlation coefficient of 0.84 and ICCa of 0.92
(excellent agreement). The mean  SD difference between
observers was 0.022 0.175 cm1. Interobserver reproducibility
Relative
Change
Post–Pre (%)
Relative
Change
FU–Post (%)
Relative
Change
FU–Pre (%)
p Value* p Value† p Value‡Median p1 Median p2 Median p3
15.3 0.01 8.4 0.01 3.4 0.05 0.11 0.01 0.01
21.9 0.01 1.9 0.54 26.1 0.01
23.1 0.01 10.7 0.30 19.7 0.11 0.09 0.93 0.27
39.9 0.01 11.5 0.27 39.0 0.01
17.4 0.01 11.3 0.01 3.9 0.16 0.02 0.01 0.01
31.8 0.01 3.8 0.01 26.9 0.01
29.6 0.01 4.6 0.26 0.3 0.51 0.06 0.51 0.01
51.0 0.01 3.7 0.72 49.9 0.01
solute difference post-implantation pre-implantation; †p comparison between BVS andMPS
f the absolute difference FU pre-implantation.
plantation and follow-up; p3 paired comparison between pre-implantation and follow-up; other550)
397)
149)
112)
.53)
.14)
02)
0)
f the ab
MPS o
post-imfor angulation assessment was 0.86 for the r2 Pearson correlation
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795coefficient and 0.91 for the ICCa (excellent agreement). The
mean  SD difference between observers was 5.3°  11.2°.
iscussion
The major findings of the present study are: 1) both BVS
and MPS decreased the coronary curvature, angulation, and
systo-diastolic changes from pre- to post-implantation; 2)
from post-implantation to follow-up, the BVS significantly
increased the artery curvature and angulation except for the
systo-diastolic changes in curvature and angulation, and the
MPS showed a slight increase in angulation but retained
the artery curvature and the systo-diastolic changes in
curvature and angulation as measured after implantation; 3)
at follow-up, the BVS presented with a minor reduction in
coronary curvature with respect to that seen before implan-
tation, although the coronary angulation and the cyclical
changes in curvature and angulation were similar to that
Figure 2. Geometric Changes in the One-Half of the Population With Highe
Individual changes of the coronary geometry in the top one-half part of the p
sents the median value. p*  0.01, comparison of the absolute differences po
scaffolds; MPS  metallic platform stents.seen before implantation; and 4) from pre-implantation tofollow-up, the MPS presented with an important reduction
in all geometric parameters. These results were larger and
more evident when the one-half of the population with
higher values of curvature and angulation was investigated.
To the best of our knowledge, the present study is the
first to report an increase in geometric parameters from
post-implantation to follow-up in scaffolded segments. At
6- or 12-month follow-up, the anatomical configuration of
the arteries treated with the ABSORB BVS allowed resto-
ration of coronary geometry to values close to those mea-
sured before implantation. However, these differences were
slightly different according to the follow-up. Patients with
angiographic control at 12 months tended to show larger
changes in geometric parameters compared with patients
with angiographic control at 6 months. Figure 5 shows the
changes in coronary geometry in 2 patients treated with the
BVS and imaged at different follow-up periods (6 and 12
es of Curvature and Angulation Before Implantation
ion with higher values of curvature and angulation. The black line repre-
lantation – follow-up between BVS and MPS. BVS  bioresorbable vascularr Valu
opulat
st-impmonth). The most plausible explanation for the coronary
the ab
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796geometric changes observed in the present study is the
gradual reduction in artery support and disappearance of the
mechanical integrity of the scaffold in most of the patients
at 6- to 12-month follow-up but especially in those patients
who underwent angiographic control at 12 months. The
first-generation BVS (1.0) showed an accelerated loss of the
artery support during the first 6 months that resulted in an
important shrinkage of the scaffold (21). The new genera-
tion of BVS (ABSORB) was redesigned to slow down the
loss of artery support, compared with its previous genera-
tion, through modification of the manufacturing processes
of the polymer and platform design (17). According to the
manufacturer, the artery wall support provided by the
ABSORB BVS is designed to gradually decrease during this
period of restoration (3 to 12 months). By the end of the
first year, the vast majority of amorphous polymer that links
Figure 3. Geometric Changes of the BVS Population at 6- and 12-Month Fo
Individual changes in artery curvature and angulation in the BVS group with 6 mo
(right; n  49). The black line represents the median value. *p  comparison ofthe crystalline lamella is hydrolyzed (15). Therefore, thescaffold has gradually lost continuity of structure, allowing
restoration of the original anatomical configuration.
The potential clinical implications related to the restoration of
the coronary geometry at follow-up are uncertain. It is noteworthy
that, before the scaffold implantation, the physiological geometry
of the treated segment developed an atherosclerotic lesion. The
first bioresorbable scaffolds implanted in human coronary arteries
(Igaki-Tamai, Igaki Medical Planning Company, Kyoto, Japan)
have fulfilled 10-year clinical and intravascular ultrasound follow-
up. The intravascular ultrasound imaging in patients that required
TLR at long-term follow-up showed the presence of neoathero-
sclerotic plaques within the scaffolded segment (22). Therefore, it
seems plausible that the restoration of the coronary anatomical
configuration similar to that seen before implantation might also
potentially restore the WSS conditions that triggered the forma-
tion of atherosclerotic plaques, if drastic preventive measures are
p
llow-up (FU) group (left; n  37) and in the BVS group with 12 months FU
solute difference after implantation  FU between 6- and 12-month FU.llow-U
nth fonot taken.
ctarge
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797Conversely, Figure 4 shows a trend toward higher values of
curvature and angulation before implantation in patients with
TLR at 12 months, compared with those without revascular-
ization. These differences mildly differed, depending on the
implanted stent/scaffold. With BVS, differences in curvature
and angulation before implantation in patients without TLR
(median values: 0.292 cm1 and 32.6°, respectively) and with
TLR at 12 months (0.280 cm1 and 33.1°, respectively) were
Figure 4. Box Plot Distribution of the Curvature and Angulation Values Rel
BVS  bioresorbable vascular scaffolds; MPS  metallic platform stents; TLR minimal (p  0.74 and p  0.99, respectively). With MPS,curvature and angulation tended to be slightly smaller in
patients without TLR (0.318 cm1 and 31.4°, respectively),
ompared with patients with TLR at 12 months (0.519 cm1
and 46.4°, respectively); p  0.48 and p  0.14, respectively.
However, the present study was not sufficiently powered to
relate coronary geometric parameters with clinical outcomes,
and these results should be interpreted carefully.
Previous reports using BMS found higher risk of reste-
o the Occurrence of TLR
t lesion revascularization.ated tnosis in angulated and curved arteries. A pre-treatment
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798angulation33.5° was found as an independent predictor of
estenosis at 10 months of follow-up (8). However, with the
se of SES, to date no study has been able to relate the
rtery curvature/angulation before implantation with a
reater neointimal response or higher risk of restenosis
7,10,23). However, most of these studies are limited to
linical outcomes at midterm follow-up. It is uncertain
hether the progressive late lumen loss experienced by SES
t long-term follow-up can modify the relationship between
rtery bend, curvature, and angulation and stent restenosis
t longer-term follow-up. The first-generation SES has
hown a progressive reduction of MLD from 6 to 18
onths of 0.28 mm, whereas the delayed late lumen loss
as smaller with the first-generation PES in the same
eriod (0.10 mm; p  0.01) (12). The Xience everolimus-
luting stent has also been associated with a progressive
eduction in the MLD from 6 to 24 months (delayed late
umen loss of 0.16 mm) and therefore can also be influenced
y the effect of WSS at long-term follow-up (24).
Study limitations. The first limitation of the present study is
the use of 2-dimensional images to assess the geometric
parameters of coronary arteries. Coronary arteries have a
3-dimensional geometric shape that is in continuous move-
Figure 5. Geometric Changes in Curvature and Angulation in 2 Patients Tr
A and B present different patients with signiﬁcant lesions in the mid right corona
from pre- to post-bioresorbable vascular scaffold (BVS) implantation. From pre-imp
curvature and angulation. At 12-month follow-up, the patient in B presented withment (4-dimensional), despite the use of the least foreshort- tened view. For these reasons, the 2-dimensional analysis of
coronary geometry is clearly biased by foreshortening of the
angiographic views. However, a reliable 3-dimensional recon-
struction of coronary arteries, based on angiographic images,
requires a biplane system or rotational angiography (25,26).
Almost all images of patients included in the ABSORB and
SPIRIT trials were acquired with monoplane angiograms in
such way that the 3-dimensional reconstruction would not
have been reliable. Second, the non-normal distribution of
curvature and angulation values, with a relatively high number
of extreme values, caused a moderate variability for repeated
measures between different observers when extreme values of
curvature and angulation were assessed. The exclusion of
extreme curved and angulated lesions (curvature0.900 cm1
and angulation 90°) substantially improved the variability
between observers to 0.016  0.086 cm1 for curvature and
.3 7.2° for angulation. The results of the present study were
lso reproducible (data not shown), taking into account the
nterobserver variability for repeated measurements (2 SD),
ith and without extreme values. The third limitation is the
mall number of patients included in our study. The possible
elationship between coronary geometry and clinical outcomes
eported in the present study is clearly underpowered and needs
With the BVS and Followed at 6 and 12 Months
ry. Patients in A and B demonstrated a reduction in curvature and angulation
ion to 6-month follow-up, the patient in A remained with similar values of
er increase in curvature and angulation than that seen before implantation.eated
ry arte
lantato be interpreted with caution. Finally, the fourth limitation of
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799the study is the difference in the time of follow-up of the
ABSORB trial patients. It was decided, as per protocol, to split
the population into 2 groups to assess the bioresorption process
with multiple intravascular imaging techniques in different
time-points. Although a possible restoration of the coronary
artery to its pre-implantation anatomical configuration in
patients treated with metallic stents at 12-month follow-up
seems improbable, we do not have angiographic control at 12
months for MPS SPIRIT patients.
Conclusions
At midterm follow-up, the BVS tended to allow restoration
of the coronary geometry and systo-diastolic movements of
the coronary arteries similar to that seen before implanta-
tion. Coronary geometry and systo-diastolic movements of
coronary arteries treated with MPS remained similar to that
seen after implantation. Potential clinical benefits of restor-
ing the pre-implantation coronary anatomy will require
longer-term clinical follow-up in a larger patient group.
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